256958-81-3

Usage

Chemical structure

A piperidine ring with a 3,4-dichlorophenyl group and a BOC protecting group.

Substitution

The piperidine structure is substituted with a 3,4-dichlorophenyl group and a BOC protecting group.

Building block

Commonly used in organic synthesis for the preparation of various compounds.

Hydroxy group

Presence of a hydroxy group makes it useful for the synthesis of pharmaceuticals and agrochemicals.

Reactivity and biological activity

The 3,4-dichlorophenyl group can impart specific reactivity or biological activity to the molecule.

Protecting group

The BOC group is used to protect amines during chemical reactions.

Easy removal

The BOC protecting group can be easily removed under mild conditions to reveal the free amine group.

Versatility

1-BOC-4-(3,4-DICHLOROPHENYL)-4-HYDROXYPIPERIDINE is a versatile compound with applications in organic synthesis and the preparation of biologically active molecules.

Upstream product

• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 79175-35-2 3,4-dichlorophenylmagnesium bromide 

Downstream Products

• 21928-32-5 4-(3,4-dichlorophenyl)-4-hydroxypiperidine 

Relevant academic research and scientific papers

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION

The present invention relates to compounds of the formulae (4), (5) or (6), and their use in the treatment of central nervous system disorders.